Skip to main content

CordenPharma into oligos

CordenPharma is entering synthetic oligonucleotide manufacturing via an investment at its CordenPharma Colorado site. This will draw on its solid-phase peptide manufacturing experience and downstream processing capabilities to offer a fully integrated drug substance and drug product offer.

Subscribe to Caponago